Synergy Neo2 joins several other previously certified readers from BioTek’s current lineup – Cytation™ 5, Cytation 3, Synergy H1 and Synergy 2. Cisbio and BioTek have a long history of collaborative development, most recently in cancer research where the companies' technologies were combined to present an easy-to-use method for assessing target-based and phenotypic effects of new, potential anti-metastatic drugs.
Synergy Neo2 is designed for speed and ultra high performance, incorporating BioTek's patented Hybrid Technology™, with its independent optical paths that ensure uncompromised performance in all detection modes. Continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to 4 PMTs provide ultra-fast measurements with excellent results.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. These technologies are used to aid life science research, facilitate drug discovery, provide rapid and cost-effective analysis, and enable sensitive, accurate quantification of molecules across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations. The company is frequently honored for local accomplishments and technological innovations, including Best Places to Work in Vermont, Frost & Sullivan North American New Product Innovation Award for Workflow Solutions in Life Sciences, SelectScience’s Drug Discovery Product of the Year – Scientists' Choice Award, and a Silver Edison Award for the Cytation Cell Imaging Multi-Mode Reader.